In a move that signals a massive consolidation in the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for approximately $9.9 billion. The all-cash deal, valued at $180 per share, represents
As of February 17, 2026, Danaher Corporation (NYSE: DHR) finds itself at a pivotal juncture in its multi-decade evolution. Once the darling of the "compounding" investment community, the Washington, D.C.-based life sciences giant has recently seen its share price retreat from 2025 highs, currently trading down approximately 11% year-to-date. This volatility follows a complex narrative: [...]
The deal will entail Danaher paying $180 per share for Masimo, reflecting about 18 times Masimo’s projected 2027 earnings before interest, taxes, depreciation, and amortization.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
The convergence of consumer technology and clinical medicine has reached a fever pitch as 2025 draws to a close. A landmark report released this December by ResearchAndMarkets.com projects that the wearable AI market will see a staggering $65 billion in incremental growth by 2030, driven almost entirely by its
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately
as healthcare stocks have returned 14.6% over the past six months, topping the S&P 500 by 1.5 percentage points.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Masimo (NASDAQ:MASI) and the best and worst performers in the patient monitoring industry.
Shares of medical tech company Masimo (NASDAQ:MASI)
jumped 3.5% in the morning session after the company presented an upbeat long-term financial outlook at its 2025 Investor Day, prompting positive reactions from analysts.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
A federal jury in California has ruled that Apple Inc. (NASDAQ: AAPL) must pay Masimo Corporation (NASDAQ: MASI) $634 million for infringing a patent related to blood-oxygen reading technology.
Masimo’s third quarter results for 2025 were met with a significant negative market reaction, despite the company surpassing Wall Street’s revenue and adjusted profit expectations. Management attributed the quarter’s topline performance to robust contracting activity, with CEO Catherine Szyman highlighting “strong underlying demand” for Masimo’s healthcare technologies and an 8% year-on-year increase in shipments of technology boards and monitors. CFO Micah Young emphasized that margin expansion was primarily driven by operational improvements and cost efficiencies, partially offset by tariff-related headwinds. The company also closed the divestiture of Sound United, which provided capital for share repurchases and debt reduction.
Medical tech company Masimo (NASDAQ:MASI) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 8.2% year on year to $371.5 million. The company expects the full year’s revenue to be around $1.52 billion, close to analysts’ estimates. Its non-GAAP profit of $1.32 per share was 10.3% above analysts’ consensus estimates.
Medical tech company Masimo (NASDAQ:MASI) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 8.2% year on year to $371.5 million. The company expects the full year’s revenue to be around $1.52 billion, close to analysts’ estimates. Its non-GAAP profit of $1.32 per share was 9.9% above analysts’ consensus estimates.
